Brian Markison
2019
In 2019, Brian Markison earned a total compensation of $4.3M as President and Chief Executive Officer at RVL Pharmaceuticals plc, a 291% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $892,680 |
|---|---|
| Salary | $683,446 |
| Stock Awards | $2,762,496 |
| Total | $4,338,622 |
Markison received $2.8M in stock awards, accounting for 64% of the total pay in 2019.
Markison also received $892.7K in non-equity incentive plan and $683.4K in salary.
Rankings
In 2019, Brian Markison's compensation ranked 2,676th out of 13,971 executives tracked by ExecPay. In other words, Markison earned more than 80.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,676 out of 13,971 | 81st |
Division Manufacturing | 965 out of 5,701 | 83rd |
Major group Chemicals And Allied Products | 315 out of 2,200 | 86th |
Industry group Drugs | 256 out of 1,886 | 86th |
Industry Pharmaceutical Preparations | 189 out of 1,398 | 87th |
Source: SEC filing on April 20, 2020.
Markison's colleagues
We found three more compensation records of executives who worked with Brian Markison at RVL Pharmaceuticals plc in 2019.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019